Ro 15-1788 antagonizes the effects of diazepam in man without affecting its bioavailability.
In a double-blind, placebo-controlled three-way cross over study, the efficacy of Ro 15-1788 200 mg, a new benzodiazepine antagonist, in blocking the amnesic, cognitive, psychomotor and subjective effects of diazepam 20 mg, was investigated in a group of six healthy male volunteers. The amnesic effects of diazepam were markedly attenuated by the combined administration of Ro 15-1788. The psychomotor and subjective effects of diazepam by mouth were most pronounced 2.5 h after administration. Concurrent oral administration of Ro 15-1788 completely prevented these effects at 2.5 h. Plasma diazepam concentrations observed after administration of the combination of diazepam and the antagonist did not differ from those observed following diazepam alone.
D000293:Adolescent; D000328:Adult; D001569:Benzodiazepines / Q000037:antagonists & inhibitors*; D001570:Benzodiazepinones / Q000494:pharmacology*; D001682:Biological Availability; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000037:antagonists & inhibitors* / Q000097:blood; D004311:Double-Blind Method; D005442:Flumazenil; D006801:Humans; D007858:Learning / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects; D011597:Psychomotor Performance / Q000187:drug effects; D011897:Random Allocation; D013997:Time Factors
D001570:Benzodiazepinones; D001569:Benzodiazepines; D005442:Flumazenil; D003975:Diazepam